GGV Capital
GGV Capital is a global venture capital firm that invests in technology companies across various stages and sectors. Established in 2000, the firm has offices in Silicon Valley, Singapore, and Beijing, providing expansion capital ranging from $5 to $25 million for initial investments. GGV Capital focuses on companies operating in the U.S., China, India, Southeast Asia, Japan, Australia, Europe, and Israel.
Top Sectors
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Macau
Ironwood Pharmaceuticals
Series D in 2004
Ironwood Pharmaceuticals is a specialty pharmaceutical company focused on gastroenterology therapies. Its lead product is linaclotide, marketed as LINZESS in the United States and CONSTELLA elsewhere, for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. The company is advancing other GI candidates, including MD-7246, an oral non-opioid pain reliever for abdominal GI pain, and IW 3718, a gastric-retentive bile acid sequestrant in Phase III for GERD. Ironwood pursues collaborations to expand linaclotide’s reach in North America, China, Hong Kong, Macau, and Japan, with agreements involving Allergan and AstraZeneca and a license with Astellas for Japan. It operates an independent subsidiary, Microbia, that develops bioprocesses for pharmaceuticals and related industries. Founded in 1998, Ironwood is headquartered in Massachusetts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.